---
id: 025
title: Piperacillin-Tazobactam Spectrum and Dosing Strategies
category: antimicrobials
subcategory: penicillins
tags: [piperacillin-tazobactam, Zosyn, Pseudomonas, extended-infusion, BREAD-PA]
difficulty: medium
---

## Question

What is the spectrum of **piperacillin-tazobactam**, and what dosing strategies optimize efficacy against *Pseudomonas aeruginosa*? Use **BREAD-PA** mnemonic for coverage.

## Answer

**BREAD-PA mnemonic for piperacillin-tazobactam coverage:**

- **B**acteroides/anaerobes (excellent)
- **R**esistant Enterobacterales (ESBL - NOT reliable clinically)
- **E**nterobacterales (non-ESBL)
- **A**mpc-producing organisms (*Enterobacter*, *Serratia*, *Citrobacter*)
- **D**iverse Gram-positives (Streptococci, MSSA, Enterococcus)
- **P**seudomonas **A**eruginosa

### **Spectrum:**
- **Gram-positives:** Streptococci, MSSA, *Enterococcus* (NOT MRSA, VRE)
- **Gram-negatives:** Broadest anti-*Pseudomonas* activity among β-lactams
- **Anaerobes:** Excellent (B. fragilis, Bacteroides spp.)
- **Does NOT cover:** MRSA, VRE, ESBL (unreliable), carbapenemases, atypicals

### **Dosing Strategies for *Pseudomonas*:**

| Clinical Scenario | Dose | Infusion | Rationale |
|-------------------|------|----------|-----------|
| **Standard susceptible** | 3.375g IV q8h | 30 min | MIC ≤8 μg/mL |
| **SDD (susceptible-dose dependent)** | 4.5g IV q6h | 3 hours | MIC 16 μg/mL; FDA 2024 breakpoint |
| **Severe/CRPA** | 4.5g IV q6h | 3-4 hours or continuous | Optimize T>MIC for MIC ≤16 |
| **Augmented renal clearance** | 4.5g IV q6h | 4 hours | Critically ill with high Cr clearance |

### **Extended Infusion Benefits:**
- Achieves **≥90% PTA** (probability of target attainment) at MIC ≤16 μg/mL
- Improves T>MIC (target: free drug >50% of dosing interval)

## Key Points

- **Pip-tazo is NOT reliable for ESBL producers** (despite in vitro susceptibility)
- **Carbapenem-resistant *P. aeruginosa*:** Consider ceftolozane-tazobactam or ceftazidime-avibactam instead
- **Combination therapy:** Add aminoglycoside or fluoroquinolone for severe *Pseudomonas* infections (bacteremia, pneumonia)
- **Renal dosing:** Reduce to q8h or q12h if CrCl <40 mL/min

## Sources

- [FDA 2024 Guidance: Pip-tazo breakpoints for *P. aeruginosa*]
- [Hopkins ABX Guide: Piperacillin + Tazobactam]
- [Clin Infect Dis 2007: Extended-infusion dosing for *Pseudomonas*]

## Media

N/A
